You are here: Industry Insights > Market News > Bristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

Riociguat(625115-55-1)

Methyl [4,6-diaMino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyriMidin-5-yl]carbaMate

2-[1-(2-Fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyriMidine-4,5,6-triaMine(428854-24-4)

4,6-PyriMidinediaMine, 2-[1-[(2-fluorophenyl)Methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-(phenylazo)-

1H-Pyrazolo[3,4-b]pyridine-3-carboximidamide, 1-[(2-fluorophenyl)methyl]-, hydrochloride (1:1)

1-(2-Fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carboximidamide(256376-68-8)

Bristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer

americanpharmaceuticalreviewJanuary 22, 2017

Tag: lung cancer , Bristol-Myers Squibb

Favorites

Bristol-Myers Squibb Company announced that it has decided not to pursue an accelerated regulatory pathway for the combination of Opdivo plus Yervoy in first-line lung cancer in the U.S. based on a review of data available at this time. In order to protect the integrity of ongoing registrational studies, the company will not be providing additional details.

Previous:GSK Announces Winners of 2016 Discovery Fast Track Boston Challenge

Next:Verastem Announces Executive Leadership Appointments and Changes

Corvia Medical Achieves CE Certification for Atrial Shunt Under New EU MDR Standards

PRNewswireDecember 21, 2024

Corvia Medical, Inc.announced today that it has achieved CE certification for the Corvia® Atrial Shunt System under the latest EU Medical Device Regulations (EU MDR 2017/745).

Macrogen Consortium win tender for National Bio Big Data Project

PRNewswireDecember 23, 2024

SCG Cell Therapy partners A*STAR to accelerate RNA-based therapeutic development in Singapore

PRNewswireDecember 23, 2024

Bristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer | Pharmasources.com

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Everest Medicines LimitedDecember 20, 2024

Everest Medicines announced NMPA acceptance of NDA for VELSIPITY(R) (etrasimod) to treat moderately to severely active UC.

Bristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer

Related News

Corvia Medical Achieves CE Certification for Atrial Shunt Under New EU MDR Standards

Macrogen Consortium win tender for National Bio Big Data Project

SCG Cell Therapy partners A*STAR to accelerate RNA-based therapeutic development in Singapore

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

You may like
More>>

Bristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer

Related News

Corvia Medical Achieves CE Certification for Atrial Shunt Under New EU MDR Standards

Macrogen Consortium win tender for National Bio Big Data Project

SCG Cell Therapy partners A*STAR to accelerate RNA-based therapeutic development in Singapore

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

You may likeMore>>

You may like
More>>